Bivalirudin in ST-segment-elevation myocardial infarction: For better or worse?

Thomas A. Mavrakanas, Yiannis S. Chatzizisis

Research output: Contribution to journalArticle

Abstract

Bivalirudin and heparin are the major available parenteral anticoagulants for percutaneous coronary intervention (PCI) in ST-segment-elevation myocardial infarction. Even though hard clinical outcomes are comparable with both drugs, bivalirudin appears to be safer (less bleeding events) at the expense of lower short-term efficacy (more acute stent thrombosis events). The selection of anticoagulation during PCI in ST-segment-elevation myocardial infarction should be individualized, taking into account the patient's ischemic and bleeding risk. In patients with increased bleeding risk, bivalirudin might be preferable to heparin, whereas in complex PCI with increased risk for stent thrombosis, heparin is preferable. Further clinical studies are needed to elucidate the role of these drugs in PCI for ST-segment-elevation myocardial infarction in the era of radial approaches, new potent antiplatelet agents and the use of glycoprotein IIb/IIIa inhibitors.

Original languageEnglish (US)
Pages (from-to)893-895
Number of pages3
JournalExpert review of cardiovascular therapy
Volume13
Issue number8
DOIs
StatePublished - Aug 1 2015

Fingerprint

Percutaneous Coronary Intervention
Heparin
Hemorrhage
Stents
Thrombosis
Platelet Glycoprotein GPIIb-IIIa Complex
Platelet Aggregation Inhibitors
Pharmaceutical Preparations
Anticoagulants
ST Elevation Myocardial Infarction
bivalirudin

Keywords

  • ST-segment elevation myocardial infarction
  • bivalirudin
  • bleeding
  • heparin
  • stent thrombosis

ASJC Scopus subject areas

  • Internal Medicine
  • Cardiology and Cardiovascular Medicine

Cite this

Bivalirudin in ST-segment-elevation myocardial infarction : For better or worse? / Mavrakanas, Thomas A.; Chatzizisis, Yiannis S.

In: Expert review of cardiovascular therapy, Vol. 13, No. 8, 01.08.2015, p. 893-895.

Research output: Contribution to journalArticle

@article{3aded8852c2244eeb1d623c4d09f5344,
title = "Bivalirudin in ST-segment-elevation myocardial infarction: For better or worse?",
abstract = "Bivalirudin and heparin are the major available parenteral anticoagulants for percutaneous coronary intervention (PCI) in ST-segment-elevation myocardial infarction. Even though hard clinical outcomes are comparable with both drugs, bivalirudin appears to be safer (less bleeding events) at the expense of lower short-term efficacy (more acute stent thrombosis events). The selection of anticoagulation during PCI in ST-segment-elevation myocardial infarction should be individualized, taking into account the patient's ischemic and bleeding risk. In patients with increased bleeding risk, bivalirudin might be preferable to heparin, whereas in complex PCI with increased risk for stent thrombosis, heparin is preferable. Further clinical studies are needed to elucidate the role of these drugs in PCI for ST-segment-elevation myocardial infarction in the era of radial approaches, new potent antiplatelet agents and the use of glycoprotein IIb/IIIa inhibitors.",
keywords = "ST-segment elevation myocardial infarction, bivalirudin, bleeding, heparin, stent thrombosis",
author = "Mavrakanas, {Thomas A.} and Chatzizisis, {Yiannis S.}",
year = "2015",
month = "8",
day = "1",
doi = "10.1586/14779072.2015.1064311",
language = "English (US)",
volume = "13",
pages = "893--895",
journal = "Expert Review of Cardiovascular Therapy",
issn = "1477-9072",
publisher = "Expert Reviews Ltd.",
number = "8",

}

TY - JOUR

T1 - Bivalirudin in ST-segment-elevation myocardial infarction

T2 - For better or worse?

AU - Mavrakanas, Thomas A.

AU - Chatzizisis, Yiannis S.

PY - 2015/8/1

Y1 - 2015/8/1

N2 - Bivalirudin and heparin are the major available parenteral anticoagulants for percutaneous coronary intervention (PCI) in ST-segment-elevation myocardial infarction. Even though hard clinical outcomes are comparable with both drugs, bivalirudin appears to be safer (less bleeding events) at the expense of lower short-term efficacy (more acute stent thrombosis events). The selection of anticoagulation during PCI in ST-segment-elevation myocardial infarction should be individualized, taking into account the patient's ischemic and bleeding risk. In patients with increased bleeding risk, bivalirudin might be preferable to heparin, whereas in complex PCI with increased risk for stent thrombosis, heparin is preferable. Further clinical studies are needed to elucidate the role of these drugs in PCI for ST-segment-elevation myocardial infarction in the era of radial approaches, new potent antiplatelet agents and the use of glycoprotein IIb/IIIa inhibitors.

AB - Bivalirudin and heparin are the major available parenteral anticoagulants for percutaneous coronary intervention (PCI) in ST-segment-elevation myocardial infarction. Even though hard clinical outcomes are comparable with both drugs, bivalirudin appears to be safer (less bleeding events) at the expense of lower short-term efficacy (more acute stent thrombosis events). The selection of anticoagulation during PCI in ST-segment-elevation myocardial infarction should be individualized, taking into account the patient's ischemic and bleeding risk. In patients with increased bleeding risk, bivalirudin might be preferable to heparin, whereas in complex PCI with increased risk for stent thrombosis, heparin is preferable. Further clinical studies are needed to elucidate the role of these drugs in PCI for ST-segment-elevation myocardial infarction in the era of radial approaches, new potent antiplatelet agents and the use of glycoprotein IIb/IIIa inhibitors.

KW - ST-segment elevation myocardial infarction

KW - bivalirudin

KW - bleeding

KW - heparin

KW - stent thrombosis

UR - http://www.scopus.com/inward/record.url?scp=84937574114&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84937574114&partnerID=8YFLogxK

U2 - 10.1586/14779072.2015.1064311

DO - 10.1586/14779072.2015.1064311

M3 - Article

C2 - 26138859

AN - SCOPUS:84937574114

VL - 13

SP - 893

EP - 895

JO - Expert Review of Cardiovascular Therapy

JF - Expert Review of Cardiovascular Therapy

SN - 1477-9072

IS - 8

ER -